Polysubstituted indozole compound as well as preparation method and application thereof

By developing a new structural selective HPK1 inhibitor, the problem of insufficient activity of HPK1 inhibitors in the prior art was solved, effective regulation of TCR signaling pathways was achieved, and the effect of immune response and anti-tumor treatment was improved.

CN118894852APending Publication Date: 2024-11-05CONVALIFE (SHANGHAI) CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410539581.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2024-04-30
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The lack of high selectivity and high activity HPK1 inhibitors in the prior art makes it difficult to effectively regulate TCR signaling pathways, affecting immune response and anti-tumor treatment.

Method used

A new structurally selective HPK1 inhibitor was developed to prepare a drug form with high activity and good physical and chemical properties by providing specific compound structures and pharmaceutical compositions, using synthetic methods such as Suzuki coupling and Perkin reaction.

Benefits of technology

It provides a highly selective and highly active HPK1 inhibitor that can effectively regulate TCR signaling pathways and potentially improve immune response and anti-tumor treatment effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004820681350000021
    Figure BDA0004820681350000021
  • Figure BDA0004820681350000041
    Figure BDA0004820681350000041
  • Figure BDA0004820681350000051
    Figure BDA0004820681350000051
Patent Text Reader

Abstract

The invention discloses a polysubstituted pyrrolo [2, 3-b] pyridine or pyrazolo [2, 3-b] pyridine compound as well as a preparation method and application thereof, and the compound has hematopoietic progenitor cell kinase 1 (HPK1) inhibitory activity, and can be used for preparing a compound for treating hematopoietic progenitor cell kinase 1 (HPK1). The compound can be used for treating autoimmune diseases and inflammations of acute myeloid leukemia, liver cancer, stomach cancer, lung cancer, colon cancer, bladder epithelial cancer, breast cancer, cervical cancer, pancreatic cancer, melanoma, systemic lupus erythematosus and psoriatic arthritis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical chemistry, and in particular to a compound that can be used as an inhibitor of hematopoietic progenitor cell kinase 1 (HPK1) and a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the same, and a preparation method and application thereof. Background Art

[0002] HPK1, also known as MAP4K1, is a serine / threonine kinase and a member of the MAP4K family. In addition, there are 5 other members in its family, including MAP3K2, MAP4K3, MAP4K4, MAP4K5, and MAP4K6. HPK1 can bind to many adaptor proteins, such as the SLP-76 family, CARD11, HIS, HIP-55, GRB2 family, LAT, CRK family, etc., to interact and activate the JNK / SAPK signaling pathway of hematopoietic stem cells, thereby negatively regulating the TCR pathway. MAP4K3, also known as GLK kinase, has a biological effect that is exactly opposite to that of HPK1. GLK can promote the activation of the TCR pathway by binding to downstream adaptor proteins. Therefore, we need to screen for inhibitors of HPK1 that are selective for GLK.

[0003] The main processes in which HPK1 participates in regulating TCR are as follows: (1) TCR binds to extracellular antigens through MHC, thereby activating the TCR pathway to transmit signals to downstream adaptor protein molecules; (2) SLP-76 activated by adaptor protein tyrosine kinases Lck and Zap70 then phosphorylates HPK1; (3) Activated HPK1 then phosphorylates the receptor protein SLP-76; (4) The phosphorylation reaction of SLP-76 provides multiple protein binding sites for the 14-3-3 (TCR pathway inhibitory protein) receptor protein to form a complex; (5) The SLP-76 phosphorylated complex participates in the downregulation of the Erk signaling pathway and is connected to the ubiquitination degradation process of SLP-76, thereby leading to a decrease in the TCR signaling pathway and T cell proliferation. In summary, HPK1 can negatively regulate the TCR signaling pathway. Therefore, HPK1 can serve as a new regulatory mechanism for T cell-mediated immune responses and become a new research and development hotspot for immune anti-tumor.

[0004] Due to its important role in immunity, HPK1 inhibitors play an important role in malignant solid tumors or blood cancers (such as acute myeloid leukemia, bladder cancer, breast cancer, colon cancer, lung cancer, pancreatic cancer, melanoma), autoimmune diseases (such as systemic lupus erythematosus, psoriatic arthritis) and inflammatory responses.

[0005] Currently, there is no drug targeting HPK1 on the market. In order to better meet the huge clinical needs, we aim to develop highly selective and highly active HPK1 inhibitors. The present invention will provide a novel structure of selective HPK1 inhibitors with good physicochemical properties and drug-forming properties. Summary of the invention

[0006] To achieve the above object, the technical solution adopted by the present invention is:

[0007] The present invention provides a compound having a structure shown in Formula I or Formula II, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof:

[0008]

[0009] in:

[0010] R 1 Selected from C 1-6 Alkyl, amino, monosubstituted or disubstituted amine, the monosubstituted amine is selected from methylamine, ethylamine, trifluoroethylamine, isopropylamine, cyclopropylamine, the disubstituted amine is selected from dimethylamine, diethylamine, azetidine, tetrahydropyrrole or substituted tetrahydropyrrole, the substituent of the substituted tetrahydropyrrole is selected from C 1-3 Alkyl or halogen, alkoxy (preferably the alkoxy is selected from C 1-3 alkoxy), amino, alkylamino (preferably the alkylamino is selected from C 1-3 alkylamino), piperidine or substituted piperidinyl, wherein the substituent of the substituted piperidinyl is selected from C 1-3 Alkyl or halogen, hydroxyl, alkoxy (preferably the alkoxy is selected from C 1-3 alkoxy), amino, alkylamino (preferably the alkylamino is selected from C 1-3 alkylamino), morpholine or substituted morpholinyl, wherein the substituent of the substituted morpholinyl is selected from C 1-3 Alkyl or halogen, hydroxyl, alkoxy (preferably the alkoxy is selected from C 1-3 alkoxy), amino, alkylamino (preferably the alkylamino is selected from C 1-3 alkylamino), piperazine, substituted piperazinyl, wherein the substituent of the substituted piperazinyl is selected from C 1-3 Alkyl or halogen, hydroxyl, alkoxy (preferably the alkoxy is selected from C 1-3 alkoxy), amino, alkylamino (preferably the alkylamino is selected from C 1-3 alkylamino groups);

[0011] R 2 is selected from amino or alkoxyacyl protected amino, wherein the alkoxy is C 1-6Alkoxyacyl;

[0012] R 3 is selected from hydrogen, halogen, methyl, trifluoromethyl;

[0013] R 4 Selected from hydrogen, halogen, C 1-6 alkyl;

[0014] R 5 is selected from hydrogen, halogen, methyl, trifluoromethyl;

[0015] R 6 Selected from hydrogen, halogen, C 1-6 Alkoxyacyl;

[0016] R 7 is selected from hydrogen, methoxymethylene, 2-(trimethylsilyl)ethoxymethylene, 2-tetrahydropyranyl, benzyl, p-methoxybenzyl, tert-butoxyacyl, benzenesulfonyl, toluenesulfonyl;

[0017] R 8 Selected from hydroxyl, C 1-6 Alkoxy, amine, hydroxylamine, C 1-6 Alkoxyamino, cyano, monosubstituted or disubstituted amine, wherein the monosubstituted amine is selected from methylamino, ethylamino, trifluoroethylamino, isopropylamino, cyclopropylamino, polyhydroxy substituted C 1-6 Alkyl, the disubstituted amine group is selected from dimethylamino, diethylamino, azetidine, tetrahydropyrrole, piperidine, morpholine, piperazine, NC 1-3 Alkylpiperazine;

[0018] X is selected from CH, C-halogen or N;

[0019] L is selected from C 1-3 Alkylene, C 2-3 Alkenylene, C 2-3 an alkynyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group or a 3-7 membered heterocyclic group, wherein the substituent of L is selected from halogen, C 1-4 Alkyl, C 1-4 Alkoxy;

[0020] Y is selected from oxygen, sulfur or NH;

[0021] Z is selected from nitrogen or -CR 9 ;

[0022] R 9 is selected from hydrogen and halogen;

[0023] Preferably, the halogen is a fluorine, chlorine, bromine or iodine atom.

[0024] Further, the present invention provides a compound having a structure as shown in Formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof:

[0025] in:

[0026] R 1 Selected from C 1-6 Alkyl, amino, monosubstituted or disubstituted amine, the monosubstituted amine is selected from methyl, ethyl, trifluoroethyl, isopropyl, cyclopropyl, and the disubstituted amine is selected from dimethylamino, diethylamino, azetidine, tetrahydropyrrole, piperidine, and morpholine;

[0027] R 2 is selected from amino or alkoxyacyl protected amino, wherein the alkoxy is C 1-6 Alkoxyacyl;

[0028] R 3 is selected from hydrogen, halogen, methyl, trifluoromethyl;

[0029] R 4 Selected from hydrogen, halogen, C 1-6 alkyl;

[0030] R 5 is selected from hydrogen, halogen, methyl, trifluoromethyl;

[0031] R 6 Selected from hydrogen, halogen, C 1-6 Alkoxyacyl;

[0032] R 7 is selected from hydrogen, methoxymethylene, 2-(trimethylsilyl)ethoxymethylene, 2-tetrahydropyranyl, benzyl, p-methoxybenzyl, tert-butoxyacyl, benzenesulfonyl, toluenesulfonyl;

[0033] R 8 Selected from hydroxyl, C 1-6 Alkoxy, amine, hydroxylamine, C 1-6 Alkoxyamino, monosubstituted or disubstituted amine, the monosubstituted amine is methylamino, ethylamino, trifluoroethylamino, isopropylamino, cyclopropylamino, and the disubstituted amine is selected from dimethylamino, diethylamino, azetidine, tetrahydropyrrole, piperidine, and morpholine;

[0034] X is selected from CH, C-halogen or N, wherein the halogen is a fluorine, chlorine, bromine or iodine atom;

[0035] L is selected from C 1-3 Alkylene, alkenyl, alkynyl, aryl, heteroaryl or 3-7 membered heterocyclic group;

[0036] Y is selected from oxygen, sulfur or NH;

[0037] Z is nitrogen or -CR 9 ;

[0038] R 9 Selected from hydrogen and halogen.

[0039] The present invention further provides a compound of formula I or II, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein L is selected from C2 alkylene, C2 alkenylene, C2 alkynylene, phenyl, phenyl substituted with a halogen atom, C 1-3 Alkyl-substituted phenyl, pyridyl, halogen-substituted pyridyl, C 1-3 Alkyl-substituted pyridyl, or 3-7 membered heterocyclic group.

[0040] Further, the present invention provides a compound of the structure shown in Formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein the compound of the structure shown in Formula I has the following structure:

[0041]

[0042]

[0043]

[0044]

[0045]

[0046] Another object of the present invention is to provide a method for preparing the compound as shown in the general formula I.

[0047] When the linking group L shown in the general formula (I) is an alkenyl group, i.e. IA, the present invention provides a synthesis method as follows:

[0048] 4) Suzuki coupling of intermediate II with arylboronic acid III to obtain intermediate IV

[0049] 5) Intermediate IV is reacted with malonic acid (V) to obtain intermediate VI

[0050] 6) The carboxylic acid of intermediate V is condensed with amine and then deprotected to obtain the target compound IA

[0051]

[0052] When the linking group L of the compound represented by general formula (I) is an alkenyl group, i.e. IA, another synthesis method of the present invention is as follows:

[0053] 1) Intermediate IV is reacted with malonic acid (V) to obtain intermediate VII

[0054] 2) The carboxylic acid of intermediate VII undergoes condensation reaction with amine to obtain intermediate VIII

[0055] 3) Suzuki coupling of intermediate VIII and arylboronic acid III to obtain target compound IA

[0056]

[0057] When the linking group L of the compound represented by the general formula (I) is an alkylene group, that is, IB, the double bond of IA is hydrogenated to obtain IB.

[0058]

[0059] When the linking group L of the compound represented by the general formula (I) is an aryl group or a heteroaryl group, and Y is oxygen, that is, IC, a synthesis method provided by the present invention is as follows:

[0060] 1) Intermediate IX is reacted with aryl boronic acid X (taking 4-carboxyphenylboronic acid as an example) to obtain intermediate XI by Suzuki reaction

[0061] 2) The carboxylic acid of intermediate XI undergoes condensation reaction with amine to produce intermediate XII

[0062] 3) Suzuki coupling of intermediate XII and arylboronic acid III to obtain target compound IC

[0063]

[0064] When the compound represented by the general formula (II) has a connecting group L that is an aryl group or a heteroaryl group (taking a phenyl group as an example), and Y is oxygen and R 8 When it is a substituted amino group, i.e., II-D, the present invention provides a synthesis method as follows:

[0065] 1) Reduce the carbonyl group of intermediate XII with borane or lithium aluminum hydride to obtain intermediate XIII

[0066] 2) Suzuki coupling of intermediate XIII and arylboronic acid III to obtain target compound II-D

[0067]

[0068] Furthermore, the present invention provides a pharmaceutical composition comprising a compound having a structure shown in the above formula I or formula II, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof and a pharmaceutically acceptable excipient.

[0069] Furthermore, the present invention provides the use of the compound having the structure shown in the above formula I or formula II, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or the pharmaceutical composition thereof in the preparation of a serine / threonine kinase (HPK1) inhibitor.

[0070] Furthermore, the present invention provides the use of the compound of the structure shown in the above formula I or formula II, or its pharmaceutically acceptable salt, or its stereoisomer or the above-mentioned pharmaceutical composition in the preparation of drugs for treating cancer, autoimmune diseases or inflammatory diseases.

[0071] Furthermore, the cancer mentioned above in the present invention is selected from solid tumors or blood cancers.

[0072] Furthermore, the present invention provides that the above-mentioned disease is selected from acute myeloid leukemia, bladder epithelial carcinoma, breast cancer, colon cancer, lung cancer, pancreatic cancer, melanoma, systemic lupus erythematosus, psoriasis, arthritis and inflammatory response.

[0073] Compared with the prior art, the present invention has the following beneficial effects:

[0074] The present invention provides a novel selective HPK1 inhibitor having higher activity, good physicochemical properties and drug-forming properties.

[0075] Definitions and explanations of terms in the present invention:

[0076] The term "pharmaceutically acceptable salt" refers to salts of compounds of the invention, prepared from compounds of the invention having specific substituents with relatively nontoxic acids or bases. When the compounds of the invention contain relatively acidic functional groups, base addition salts can be obtained by contacting such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts. When the compounds of the invention contain relatively basic functional groups, acid addition salts can be obtained by contacting such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts, such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts, such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid and methanesulfonic acid, and salts of amino acids (such as arginine, etc.), and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic and acidic functional groups, and thus can be converted into any base or acid addition salt.

[0077] Unless otherwise specified, the term “C 1-3 "Alkoxy" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule via an oxygen atom. 1-3 Alkoxy includes C 1-2 , C 2-3 , C3 and C2 alkoxy, etc. 1-3 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.

[0078] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0079] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, which may include a variant of deuterium and hydrogen, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is oxygen (i.e., =O), it means that two hydrogen atoms are replaced. Oxygen substitution does not occur on aromatic groups. The term "optionally substituted" means that it may be substituted or not substituted, and unless otherwise specified, the type and number of the substituents may be arbitrary on the basis of chemical achievable.

[0080] The aryl groups of the present invention include phenyl or optionally substituted phenyl; the heteroaryl groups of the present invention include, but are not limited to, pyridine or optionally substituted pyridinyl.

[0081] The halogen of the present invention is selected from fluorine, chlorine, bromine or iodine. DETAILED DESCRIPTION

[0082] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further explained below in conjunction with specific implementation methods.

[0083] Example 1 Synthesis of 2-amino-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (IIIa)

[0084]

[0085] Step 1: Synthesis of 2-amino-5-bromo-N,N-dimethylbenzamide (2a)

[0086] Dissolve 2-amino-5-bromo-benzoic acid (5.00 g, 23.15 mmol) and dimethylamine (12 mL, 23.15 mmol, 2.0 M in THF) in dichloromethane (50 mL), then add DIEA (8 mL, 46.30 mmol) and HATU (8.80 g, 23.15 mmol). Stir and react for 16 hours at room temperature. Concentrate the reaction solution to obtain a crude product, mix the organic phase with silica gel, and purify it with normal phase (petroleum ether / ethyl acetate = 1:1) to obtain the target compound (white solid, 5 g, yield 89.3%). LC-MS (ESI) m / z 245.2 [M+H] + ; 1 H NMR (400MHz, DMSO-d6): δ7.21(dd,1H),7.10(d,1H),6.66(d,1H),5.32(s,2H),2.91(s,6H).

[0087] Step 2: 2-amino-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

[0088] Dissolve tert-butyl (4-bromo-2-(dimethylcarbamoyl)phenyl)carbamate (2.00g, 6.17mmol), bis(boronic acid pinacol) ester (2.34g, 9.22mmol) and potassium acetate (1.80g, 18.51mmol) in 60mL 1,4-dioxane solution, evacuate the reaction solution and replace it with nitrogen three times. Then add Pd(dppf)Cl2 (0.50g, 0.62mmol), evacuate the reaction solution again and replace it with argon three times. Heat to 90℃ and stir the reaction for 16 hours. The reaction solution is quenched with water (20mL), extracted with ethyl acetate (40mL*3), washed with brine (20mL*3), and dried over anhydrous sodium sulfate. The organic phase is spin-dried and mixed with silica gel and purified by normal phase. (Petroleum ether / ethyl acetate = 4:1) to obtain the target compound (white solid, 2.00g, yield 83.3%). LC-MS (ESI) m / z 291.2 [M+H] + .

[0089] Example 2 Synthesis of tert-butyl 2-(dimethylcarbamoyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanecyclopentane-2-yl)phenyl)carbamate (IIIb)

[0090]

[0091] Step 1: tert-Butyl (4-bromo-2-(dimethylcarbamoyl)phenyl)carbamate

[0092] Dissolve 2-amino-5-bromo-N,N-dimethylbenzamide (2.50 g, 10.33 mmol) and di-tert-butyl dicarbonate (4.50 g, 20.66 mmol) in 50 mL of tert-butyl alcohol. Stir and react at 90°C for 16 hours. Concentrate the reaction solution to obtain a crude product, which is directly mixed with silica gel and purified by normal phase (petroleum ether / ethyl acetate = 2:1) to obtain the target compound (white solid, 2.84 g, yield 80.4%). LC-MS (ESI) m / z 289.0 [M-56+H] + ; 1 H NMR (400MHz, DMSO-d6): δ8.83(s,1H),7.60-7.47(m,2H),7.43(d,1H),2.93(s,3H),2.86(s,3H),1.44(s,9H).

[0093] Step 2: tert-Butyl 2-(dimethylcarbamoyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate

[0094] Dissolve tert-butyl (4-bromo-2-(dimethylcarbamoyl)phenyl)carbamate (2.00g, 6.17mmol), bis(boronic acid pinacol) ester (2.34g, 9.22mmol) and potassium acetate (1.80g, 18.51mmol) in 60mL 1,4-dioxane solution, evacuate the reaction solution and replace it with nitrogen three times. Then add Pd(dppf)Cl2 (0.50g, 0.62mmol), evacuate the reaction solution again and replace it with argon three times. Heat to 90℃ and stir the reaction for 16 hours. The reaction solution is quenched with water (20mL), extracted with ethyl acetate (40mL*3), washed with brine (20mL*3), and dried over anhydrous sodium sulfate. The organic phase is spin-dried and mixed with silica gel and purified by normal phase. (Petroleum ether / ethyl acetate = 4:1) to obtain the target compound (white solid, 2.00g, yield 83.3%). LC-MS (ESI) m / z 391.2 [M+H] + ; 1 H NMR (400MHz, CD3OD): δ7.75(s,2H),7.64(s,1H),3.08(s,3H),2.98(s,3H),1.46(s,9H)1.33(s,12H).

[0095] Example 3 2-Amino-3-fluoro-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (IIIc)

[0096]

[0097] Step 1: 2-Amino-3-fluoro-N,N-dimethylbenzamide

[0098] Dissolve 2-amino-3-fluorobenzoic acid (5.00 g, 32.50 mmol) and dimethylamine (16.25 mL, 32.50 mmol, 2.0 Min THF) in dichloromethane (50 mL), then add DIEA (11 mL, 65.00 mmol) and HATU (13.20 g, 32.50 mmol). Stir and react for 16 hours at room temperature. Concentrate the reaction solution to obtain a crude product, mix the organic phase with silica gel, and purify it with normal phase (petroleum ether / ethyl acetate = 1:1) to obtain the target compound (yellow liquid, 5.80 g, yield 91.4%) LC-MS (ESI) m / z 183.2 [M+H] + ; 1 H NMR (400MHz, DMSO-d6): δ7.08-7.02(m,1H),6.87(d,J=7.6Hz,1H),6.60-6.55(m,1H),5.13(s,2H),2,93(s,6H).

[0099] Step 2: 2-Amino-5-bromo-3-fluoro-N,N-dimethylbenzamide

[0100] Dissolve 2-amino-3-fluoro-N,N-dimethylbenzamide (5.00 g, 27.50 mmol) and N-bromosuccinimide (5.40 g, 30.25 mmol) in 275 mL of acetic acid. Stir and react for 16 hours at room temperature. Concentrate the reaction solution to obtain a crude product, directly mix the sample on silica gel, and purify it with normal phase (petroleum ether / ethyl acetate = 2:1) to obtain the target compound (yellow solid, 2.80 g, yield 39.0%) LC-MS (ESI) m / z 261.0 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ7.35-7.32(m,1H),7.04-7.02(m,1H),5.30(s,2H),2.93(s,6H).

[0101] Step 3: 2-Amino-3-fluoro-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

[0102] 2-Amino-5-bromo-3-fluoro-N,N-dimethylbenzamide (1.93g, 7.41mmol), biboronic acid pinacol ester (2.83g, 11.12mmol) and potassium acetate (2.20g, 22.23mmol) were dissolved in 45mL 1,4, dioxane solution, the reaction solution was evacuated and replaced with argon three times. Then Pd(dppf)Cl2 (0.60g, 0.74mmol) was added, the reaction solution was evacuated again and replaced with argon three times. Heat to 95℃ and stir overnight. The reaction solution was quenched with water (20mL), extracted with ethyl acetate (40mL*3), washed with brine (20mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel and purified by normal phase. (Petroleum ether / ethyl acetate = 4:1) to obtain the target compound (yellow solid, 1.50g, yield 86.6%). LC-MS (ESI) m / z 309.1 [M+H] + ; 1 H NMR (400MHz, DMSO-d6): δ7.19-7.12(m,2H),5.60(s,2H),2.91(s,6H),1.26(s,12H).

[0103] Example 4 Synthesis of 6-amino-2-fluoro-N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (IIId)

[0104]

[0105] Step 1: 2-Amino-6-fluorobenzoic acid

[0106] A suspension of 2-amino-6-fluorobenzoic acid (6 g, 38.7 mmol) in chloroform (80 mL) was cooled in ice. Bromine (2.19 mL, 42.6 mmol) was added dropwise and the mixture was stirred at 0°C for 0.5 hours and then at room temperature for 16 hours. The solid was filtered, washed with dichloromethane and dried under vacuum at 40°C to give the title compound (12.3 g). 1 H-NMR(400MHz,DMSO-d6)δ7.98-7.94(m,1H),7.45-7.40(m,1H),6.61-6.58(m,2H).LC-MS(ESI,m / z)234.0[M+H] + .

[0107] Step 2: 6-Amino-3-bromo-2-fluoro-N,N-dimethylbenzamide

[0108] DIPEA (16.4 mL, 96 mmol) was added to a suspension of the crude product from step 1 (10.28 g) in anhydrous dichloromethane (100 mL) to give a solution. HATU (18.2 grams, 48 ​​mmol) was added and the mixture was stirred for 5 minutes, then dimethylamine (2M in tetrahydrofuran, 24.0 mL, 48 mmol) was added under cooling in a cold water bath. The mixture was stirred at room temperature for 3 hours, then washed with 1 M sodium hydroxide and brine. The aqueous phase was stripped twice with dichloromethane. The combined organic phases were dried (Na2SO4) and evaporated. The residue was chromatographed on silica gel, eluted with an ethyl acetate / cyclohexane gradient to give a mixture of the title compounds (8.34 g). 1 H-NMR(400MHz, DMSO-d6)δ7.31-7.27(m,1H),6.50-6.47(m,1H),5.51(s,2H),2.98(s,3H),2.84-2.81(s,3H); LCMS(ES,m / z)263.1[M+H] + .

[0109] Step 3: 6-amino-2-fluoro-N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide

[0110] Dissolve 6-amino-3-bromo-2-fluoro-N,N-dimethylbenzamide (1.93g, 7.41mmol), biboronic acid pinacol ester (2.83g, 11.12mmol) and potassium acetate (2.20g, 22.23mmol) in 45mL 1,4, dioxane solution, evacuate the reaction solution and replace it with argon three times. Then add Pd(dppf)Cl2 (0.60g, 0.74mmol), evacuate the reaction solution again and replace it with argon three times. Heat to 95℃ and stir overnight. Quench the reaction solution with water (20mL), extract with ethyl acetate (40mL*3), wash with brine (20mL*3), and dry with anhydrous sodium sulfate. The organic phase is spin-dried and mixed with silica gel, and purified by normal phase. (Petroleum ether / ethyl acetate = 4:1) to obtain the target compound (yellow solid, 1.50g, yield 86.6%). 1 H-NMR(400MHz,DMSO-d6)δ7.35-7.30(m,1H),6.55-6.48(m,1H),5.72(s,2H),2 .92-2.91(s,3H),2.86(s,3H),1.28-1.91(m,12H).LCMS(ESI,m / z)309.2[M+H] + .

[0111] Example 5: Synthesis of tert-butyl (2-(dimethylcarbamoyl)-3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (IIIe)

[0112]

[0113] Step 1: tert-Butyl (4-bromo-2-(dimethylcarbamoyl)-3-fluorophenyl)carbamate

[0114] Dissolve 6-amino-3-bromo-2-fluoro-N,N-dimethylbenzamide (2.50 g, 10.33 mmol) and di-tert-butyl dicarbonate (4.50 g, 20.66 mmol) in 50 mL of tert-butyl alcohol. Stir and react at 90°C for 16 hours. Concentrate the reaction solution to obtain a crude product, which is directly mixed with silica gel and purified by normal phase (petroleum ether / ethyl acetate = 2:1) to obtain the target compound (white solid, 2.84 g, yield 80.4%). LC-MS (ESI) m / z 361.1 [M+H] + .

[0115] Step 2: tert-Butyl (2-(dimethylcarbamoyl)-3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate

[0116] Dissolve tert-butyl (4-bromo-2-(dimethylcarbamoyl)-3-fluorophenyl)carbamate (2.00 g, 6.17 mmol), bis(boronic acid pinacol) ester (2.34 g, 9.22 mmol) and potassium acetate (1.80 g, 18.51 mmol) in 60 mL of 1,4-dioxane solution, evacuate the reaction solution and replace it with nitrogen three times. Then add Pd(dppf)Cl2 (0.50 g, 0.62 mmol), evacuate the reaction solution again and replace it with argon three times. Heat to 90°C and stir the reaction for 16 hours. The reaction solution is quenched with water (20 mL), extracted with ethyl acetate (40 mL*3), washed with brine (20 mL*3), and dried over anhydrous sodium sulfate. The organic phase is spin-dried and mixed with silica gel and purified by normal phase. (Petroleum ether / ethyl acetate = 4:1) to obtain the target compound (white solid, 2.00 g, yield 83.3%). LC-MS (ESI) m / z 409.2 [M+H] + ; 1H NMR(400MHz,DMSO-d6)δ12.31(s,1H),8.77(s,1H),8.60(s,1H),8.50(s,1H),8.10(s,1H),7.85-7.81(m,2H) ,7.75-7.73(m,2H)7.60(s,2H),6.97(s,1H),6.48(d,J=16.0Hz,1H),3.00(s,3H),2.96(s,3H),1.47(s,9H).

[0117] Example 6 Preparation of 2-amino-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinamide (IIIf)

[0118]

[0119] Step 1: Preparation of 2-amino-5-bromo-N,N-dimethylnicotinamide

[0120] Dissolve 2-amino-5-nicotinic acid (5.00 g, 32.50 mmol) and dimethylamine (16.25 mL, 32.50 mmol, 2.0 M in THF) in dichloromethane (50 mL), then add DIEA (11 mL, 65.00 mmol) and HATU (13.20 g, 32.50 mmol). Stir and react for 16 hours at room temperature. Concentrate the reaction solution to obtain a crude product, mix the organic phase with silica gel, and purify it with normal phase (petroleum ether / ethyl acetate = 1:1) to obtain the target compound (yellow liquid, 5.80 g, yield 91.4%) LC-MS (ESI) m / z 244.2M+H] + .

[0121] Step 2: Preparation of 2-amino-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinamide

[0122] 2-Amino-5-bromo-N, N-dimethylnicotinamide (1.93g, 7.41mmol), biboronic acid pinacol ester (2.83g, 11.12mmol) and potassium acetate (2.20g, 22.23mmol) were dissolved in 45mL 1,4, dioxane solution, the reaction solution was evacuated and replaced with argon three times. Then Pd(dppf)Cl2 (0.60g, 0.74mmol) was added, the reaction solution was evacuated again and replaced with argon three times. Heat to 95℃ and stir overnight. The reaction solution was quenched with water (20mL), extracted with ethyl acetate (40mL*3), washed with brine (20mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel and purified by normal phase. (Petroleum ether / ethyl acetate = 4:1) to obtain the target compound (yellow solid, 1.50g, yield 86.6%). LC-MS (ESI) m / z 292.1 [M+H] + .

[0123] Example 7 Preparation of tert-butyl (3-(dimethylcarbamoyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)carbamate (IIIg)

[0124]

[0125] Step 1: tert-Butyl (5-bromo-3-(dimethylcarbamoyl)pyridin-2-yl)carbamate

[0126] Dissolve 2-amino-5-bromo-N, N-dimethylnicotinamide (5.0 g, 20.0 mmol) and di-tert-butyl dicarbonate (9.0 g, 41.67 mmol) in 100 mL of tert-butyl alcohol. Stir and react at room temperature at 90°C for 16 hours. Concentrate the reaction solution to obtain a crude product, directly mix the sample on silica gel, and purify it with normal phase (petroleum ether / ethyl acetate = 2:1) to obtain the target compound (white solid, 6.20 g, yield 90.4%). LC-MS (ESI) m / z 344.1 [M+H] +.

[0127] Step 2: tert-Butyl (3-(dimethylcarbamoyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)carbamate

[0128] Dissolve tert-butyl (5-bromo-3-(dimethylcarbamoyl)pyridin-2-yl)carbamate (6.0 g, 17.43 mmol), biboronic acid pinacol ester (5.08 g, 20.0 mmol) and potassium acetate (4.40 g, 44.46 mmol) in 1,4-dioxane (100 mL), evacuate the reaction solution and replace it with argon three times. Then add Pd(dppf)Cl2 (0.60 g, 0.74 mmol), evacuate the reaction solution again and replace it with argon three times. Heat to 95°C and stir overnight. Quench the reaction solution with water (20 mL), extract with ethyl acetate (40 mL*3), wash with brine (20 mL*3), and dry with anhydrous sodium sulfate. The organic phase is spin-dried and mixed with silica gel and purified by normal phase. (Petroleum ether / ethyl acetate = 4:1) to obtain the target compound (yellow solid, 5.61 g, yield 86.6%). LC-MS (ESI) m / z 392.1 [M+H]+.

[0129] Example 8 (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (IA-1)

[0130]

[0131] Step 1: Preparation of tert-butyl (2-(dimethylcarbamoyl)-4-(3-formyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)carbamate

[0132] Dissolve tert-butyl 5-bromo-3-formyl-1H-pyrrolo[2,3-b]pyridine-1-carboxylate (0.80 g, 2.46 mmol) and tert-butyl 2-(dimethylcarbamoyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (1.10 g, 2.95 mmol) in 25 mL of 1,4, dioxane solution, then add 14 mL of potassium acetate (0.72 g, 7.38 mmol) aqueous solution and Pd(dppf)Cl2 (0.20 g, 0.25 mmol). The reaction solution was evacuated and replaced with argon three times. Heat to 90 ° C and stir for 16 hours. The reaction solution was quenched with water (20 mL), extracted with ethyl acetate (30 mL*3), washed with brine (30 mL*3), and dried over anhydrous sodium sulfate. The organic phase was dried and mixed with silica gel, and purified by normal phase (petroleum ether / ethyl acetate = 1:1) to obtain the target compound (yellow solid, 0.600 g, yield 58.7%). LC-MS (ESI) m / z 409.2 [M+H] + ; 1H NMR(400MHz,DMSO-d6)δ12.80(s,1H),9.97(s,1H),8.82(s,1H),8.74-8.58(m,1H), 8.58-8.40(m,2H),7.75(s,2H),7.61(s,1H),2.99(s,3H),2.95(s,3H),1.47(s,9H).

[0133] Step 2: 3-(5-(4-tert-Butyloxycarbonyl)amino)-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid

[0134] To a pyridine solution (1.5 mL) of tert-butyl (2-(dimethylcarbamoyl)-4-(3-formyl-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)carbamate (0.10 g, 0.25 mmol) was added a solution of piperidine (0.5 mL) and malonic acid (0.52 g, 5.00 mmol), and the solution of malonic acid was dissolved in 1 mL of pyridine and 0.5 mL of piperidine. Heat to 95°C and stir to react for 16 hours. The reaction solution was quenched with water (10 mL), extracted with ethyl acetate (10 mL*3), washed with brine (10 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and the target compound was obtained by normal phase purification (dichloromethane / methanol=10:1). (Pale yellow solid, 0.10 g, yield 89.2%). LC-MS (ESI) m / z 451.1 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.31(s,1H),8.77(s,1H),8.60(s,1H),8.50(s,1H),8.10(s,1H),7.85-7.81(m,2H) ,7.75-7.73(m,1H)7.60(s,1H),6.97(s,1H),6.48(d,J=16.0Hz,1H),3.00(s,3H),2.96(s,3H),1.47(s,9H).

[0135] Step 3: (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid

[0136] 3-(5-(4-tert-butyloxycarbonyl)amino)-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (0.25 g, 0.55 mmol) was dissolved in 4 mL of HCl / dioxane, heated to 40°C, and stirred for 2 hours. The reaction solution was directly vacuum-dried to obtain a crude product, which was sent to high-performance liquid chromatography (0.1% FA) to obtain the target compound (white solid, 18.39 mg, yield 9.32%). LC-MS (ESI) m / z [M+H] + 351.0. 1 H NMR(400MHz,DMSO-d6)δ12.23(s,1H),8.51(s,1H),8.37(s,1H),8.06(s,1H),7.82(d,J=15.8Hz,1 H),7.58(d,J=6.6Hz,1H),7.47(s,1H),6.87(d,J=7.8Hz,1H),6.45(d,J=16.0Hz,1H),2.99(s,6H).

[0137] Example 9 (E)-2-amino-5-(3-(3-amino-3-oxoprop-1-en-1-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide (IA-2)

[0138]

[0139] Step 1: (E)-3-(5-(4-((tert-butoxycarbonyl)amino)-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid

[0140] N, N-diisopropylethylamine (335ul, 2.01mmol) and dicarbonyl imidazole (0.34g, 2.01mmol) were added to a solution of (E)-3-(5-(4-((tert-butoxycarbonyl)amino)-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (0.30g, 0.67mmol) in tetrahydrofuran (7mL), and the reaction solution was stirred at room temperature for 2 hours. Ammonia water (2.5mL) was then added to the reaction solution, and the reaction solution was stirred at room temperature for 2 hours. The reaction solution was concentrated, mixed with silica gel, and purified by normal phase (dichloromethane / methanol = 10:1) to obtain the target compound (light yellow solid, 0.22g, yield 73.1%). LC-MS (ESI) m / z 450.3 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ12.18(s,1H),8.80(s,1H),8.58(s,1H),8.44(s,1H),7.94(d,J=2.2Hz,1H),7.88-7.52 (m,3H),7.33(s,1H),7.04(s,1H),6.90(s,1H),6.68(d,J=15.8Hz,1H),3.00(s,3H),2.96(s,3H),1.47(s,9H).

[0141] Step 2: (E)-3-(5-(4-(amino)-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylamide (IA-2)

[0142] Dissolve (E)-3-(5-(4-((tert-butoxycarbonyl)amino)-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylamide (0.12 g, 0.27 mmol) in 2 mL of ethyl acetate, and then add 2 mL of hydrochloric acid / ethyl acetate (3.0 M). Heat to 40°C and stir for 1 hour. Concentrate the reaction solution directly, then mix with silica gel and purify with normal phase (dichloromethane / methanol = 10 / 1). Obtain the target compound (white solid, 25.51 mg, yield 26.6%). LC-MS (ESI) m / z 350.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ12.13(s,1H),8.48(d,J=1.8Hz,1H),8.33(s,1H),7.88(s,1H),7. 61-7.51(m,4H),6.86(d,J=8.4Hz,2H),6.68(d,J=16.0Hz,1H),5.32(s,2H),2.98(s,6H).

[0143] Example 10 (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)-5-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (IA-3)

[0144]

[0145] Step 1: 2-amino-3-fluoro-5-(3-formyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide

[0146] Dissolve 5-bromo-3-formyl-1H-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl ester (0.91 g, 2.80 mmol) and 2-amino-3-fluoro-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (1.00 g, 3.32 mmol) in dioxane (28 mL). Then add cesium carbonate (2.70 g, 8.40 mmol) in water (5 mL), evacuate three times, and then add Pd(dppf)Cl2 (0.21 g, 0.28 mmol) to the reaction solution. Continue to evacuate three times, heat to 100 ° C, and stir for 5 hours. The reaction solution is quenched with water (20 mL), extracted with ethyl acetate (20 mL*3), washed with brine (20 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by normal phase (petroleum ether / ethyl acetate = 2:3) to obtain the target compound (brown solid, 0.60 g, yield 65.5%). LC-MS (ESI) m / z 327.1 [M+1] + ; 1 H NMR (400MHz, DMSO-d6) δ9.92 (s, 1H), 8.66 (d, J = 2.4Hz, 1H), 8.55 (d, J = 2.4Hz, 1H), 8.30 (s, 1H), 7.56-7.43 (m, 1H), 7.28 (s, 1H), 3.11 (s, 6H).

[0147] Step 2: (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)-5-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (IA-3)

[0148] Dissolve 2-amino-3-fluoro-5-(3-formyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide (0.14 g, 0.42 mmol) and malonic acid (0.44 g, 4.20 mmol) in 4 mL of pyridine solution, then add piperidine (0.4 mL) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.4 mL). Heat to 70°C and stir for 16 hours. Concentrate the reaction solution to obtain a crude product, which is purified by column chromatography to obtain the target compound (white solid, 98.3 mg, yield 70.6%). LC-MS (ESI) m / z 369.0 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ12.26(s,1H),8.55(s,1H),8.42(s,1H),8.06(d,J=2.4Hz,1H),7.80 (d,J=15.2Hz,1H),7.63(d,J=11.2Hz,1H),7.34(s,1H),6.49(d,J=16.4Hz,1H),2,98(s,6H).

[0149] Example 11 Preparation of 2-amino-5-(3-amino-3-oxo-1-en-1-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-3-fluoro-N,N-dimethylbenzamide (IA-4)

[0150]

[0151] (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)-5-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (0.30 g, 0.82 mmol) and N,N'-carbonyldiimidazole (0.20 g, 1.22 mmol) were dissolved in 5 mL of tetrahydrofuran solution, and then N,N-diisopropylethylamine (0.32 g, 1.60 mmol) was added. The reaction solution was reacted at room temperature for 2 hours. Then 0.3 mL of ammonia water was slowly added. The reaction was continued at room temperature for another 2 hours. The reaction solution was concentrated to obtain a crude product, which was purified by column chromatography to obtain the target compound ((white solid, 93.1 mg, yield 31.1%)). LC-MS (ESI) m / z 368.2 [M+1] + ; 1 H NMR(400MHz,DMSO-d6)δ12.09(s,1H),8.53(s,1H),8.35(s,1H),7.90(s,1H),7.60-7.52(m,2 H),7.34(s,1H),7.27(s,1H),6.87(s,1H),6.66(d,J=18.8Hz,1H),5.26(s,2H),2.98(s,6H).

[0152] Example 12 (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)-5-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (IA-5)

[0153]

[0154] Step 1: (E)-3-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid

[0155] Dissolve 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carboxaldehyde (0.14 g, 0.42 mmol) and malonic acid (0.44 g, 4.20 mmol) in 4 mL of pyridine solution, then add piperidine (0.4 mL) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.4 mL). Heat to 70°C and stir to react for 16 hours. Concentrate the reaction solution to obtain a crude product, which is purified by column chromatography to obtain the target compound (white solid, 98.3 mg, yield 70.6%). LC-MS (ESI) m / z 267.0 [M+H] + .

[0156] Step 2: (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)-2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (IA-5)

[0157] (E)-3-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (0.91 g, 2.80 mmol) and 2-amino-3-fluoro-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (1.00 g, 3.32 mmol) were dissolved in dioxane (28 mL). Then, a solution of cesium carbonate (2.70 g, 8.40 mmol) in water (5 mL) was added, and the mixture was vacuumed three times. Then, Pd(dppf)Cl2 (0.21 g, 0.28 mmol) was added to the reaction solution. The mixture was vacuumed three times, heated to 100°C, and stirred for 5 hours. The reaction solution was quenched with water (20 mL), extracted with ethyl acetate (20 mL*3), washed with brine (20 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel and purified by normal phase (petroleum ether / ethyl acetate=2:3) to obtain the target compound (brown solid, 0.60 g, yield 65.5%). 1 H-NMR(400MHz,DMSO-d6)δ8.37(s,1H),8.26(s,1H),8.05-8.02(m,1H),7.75-7.71(d,1H),7.40-7.35(m,1H ),6.67-6.65(m,1H),6.41-6.37(m,1H),5.45(s,2H),3.02(s,3H),2.93(s,3H).LCMS(ESI,m / z)369.0[M+H] + .

[0158] Example 13 Synthesis of (E)-6-amino-3-(3-(3-amino-3-oxoprop-1-en-1-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-fluoro-N,N-dimethylbenzamide (IA-6)

[0159]

[0160] (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)-2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (0.30 g, 0.82 mmol) and N,N'-carbonyldiimidazole (0.20 g, 1.22 mmol) were dissolved in 5 mL of tetrahydrofuran solution, and then N,N-diisopropylethylamine (0.32 g, 1.60 mmol) was added. The reaction solution was reacted at room temperature for 2 hours. Then 0.3 mL of ammonia water was slowly added. The reaction was continued at room temperature for another 2 hours. The reaction solution was concentrated to obtain a crude product, which was purified by column chromatography to obtain the target compound (white solid, 93.1 mg, yield 31.1%). 1H-NMR(400MHz,DMSO-d6)δ:12.12(1H,s),8.34(1H,s),8.25(1H,s),7.92(1H,s),7.56-7.60(1H,d),7.33-7.38(1H,m),7.29-7. 31(1H,d),6.86(1H,s),6.66-6.68(1H,d),6.57-6.61(1H,m),5.45(2H,s),3.01(3H,s),2.91(3H,s).LCMS(ESI,m / z)368.2[M+H] + .

[0161] Example 14 Synthesis of (E)-6-amino-2-fluoro-N,N-dimethyl-3-(3-(3-(methylamino)-3-oxoprop-1-en-1-yl)-1H-pyrrolo(2,3-b)pyridin-5-yl)benzamide (IA-7)

[0162]

[0163] Under nitrogen protection, (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)-2-fluorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)acrylic acid (200 mg, 0.5429 mmol) was dissolved in DMF (3 mL), HATU (309.6 mg, 0.81 mmol) and DIEA (210.5 mg, 1.63 mmol) were added, and methylamine (33.7 mg, 1.09 mmol) was added after stirring for 10 min, and stirred at room temperature for 3 hours. The reaction solution was poured into water, extracted with dichloromethane, the organic phases were combined, dried and concentrated, and purified by column chromatography to obtain the target compound (25 mg, 11.59% yield). 1H-NMR(400MHz,DMSO-d6)δ:12.11(1H,s),8.34(1H,s),8.25(1H,s),7.91(1H,s),7.88-7.89(1H,d),7.55-7.59(1H,m),7.29-7.3 3(1H,d),6.66-6.68(1H,d),6.58-6.61(1H,m),5.48(2H,s),3.01(3H,s),2.91(3H,s),2.69-2.71(3H,m).LCMS(ESI,m / z):[M+H] + =382.0.

[0164] Example 15 (E)-6-amino-2-fluoro-3-(3-(3-(methoxyamino)-3-oxoprop-1-en-1-yl)-1H-pyrrolo[2,3-b]

[0165] Synthesis of 5-pyridin-5-yl)-N,N-dimethylbenzamide (IA-8)

[0166]

[0167] Under nitrogen protection, (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)-2-fluorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)acrylic acid (300 mg, 0.64 mmol) was dissolved in DMF (3 mL), HATU (364.45 mg, 0.96 mmol) and DIEA (247.77 mg, 1.92 mmol) were added, stirred for 10 min, and then methoxyamine hydrochloride (106.07 mg, 1.28 mmol) was added, and stirred at room temperature for 3 hours. The reaction solution was poured into water, extracted with dichloromethane, the organic phases were combined, dried and concentrated, and purified by column chromatography to obtain the target compound (26 mg, 11.59% yield). 1 H-NMR(400MHz,DMSO-d6)δ12.22(1H,s),11.04-11.07(1H,d),8.38(1H,s),8.22(1H,s),7.01(1H,s),7.67-7.72(1H,d),7.31-7 .37(1H,m),6.68-6.71(1H,d),6.38-6.43(1H,m),5.50(2H,s),3.68(3H,s),3.04(3H,s),2.94(3H,s).LCMS(ES,m / z)398.1[M+H] + .

[0168] Example 16 6-amino-3-(3-(3-amino-3-oxopropyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-fluoro-N,N-dimethylbenzamide (IB-1)

[0169]

[0170] Dissolve (E)-6-amino-3-(3-(3-amino-3-oxoprop-1-en-1-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-fluoro-N,n-dimethylbenzamide (20 mg) in methanol, add 10% Pd / C, replace hydrogen with vacuum, hydrogenate at room temperature for 3 h, filter, and spin dry to obtain the target compound (18 mg). LC-MS (ESI) m / z 370.2 [M+1] + .

[0171] Example 17 4-(5-(4-amino-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid (IC-1)

[0172]

[0173] Step 1: 4-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid

[0174] Dissolve 5-bromo-3-iodo-1H-pyrrolo[2,3-b-and]pyridine (3.00 g, 7.09 mmol) and 4-(carboxyl)phenylboronic acid (1.40 g, 7.82 mmol) in 70 mL of 1,4-dioxane solution, then add K2CO3 (2.89 g, 21.30 mmol) in water (14 mL) and Pd(dppf)Cl2 (0.51 g, 0.70 mmol). The reaction solution was evacuated and replaced with argon three times. Heat to 80°C and stir for 2 hours. The reaction solution was quenched with water (20 mL), extracted with ethyl acetate (30 mL*3), washed with brine (30 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by normal phase (petroleum ether / ethyl acetate = 1:1) to obtain the target compound (white solid, 0.80 g, yield 26.7%). LC-MS (ESI) m / z 317.0 [M+H] + .

[0175] Step 2: 4-(5-(4-amino-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid

[0176] Dissolve 4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid (0.55 g, 1.28 mmol) and tert-butyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (0.55 g, 1.41 mmol) in 13 mL of 1,4-dioxane solution, then add Cs2CO3 (1.25 g, 3.84 mmol) water (2.5 mL) solution and Pd(dppf)Cl2 (0.095) g, 0.013 mmol). The reaction solution was evacuated and replaced with argon three times. Heat to 90°C and stir for 2 hours. The reaction solution was quenched with water (10 mL), extracted with ethyl acetate (10 mL*3), washed with brine (10 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by normal phase (dichloromethane / methanol = 40:1) to obtain the target compound (brown solid, 0.60 g, yield 74.8%). LC-MS (ESI) m / z 401.0 [M+H] + ; 1 H NMR (400MHz, DMSO-d6): δ12.05(s,1H),8.78(s,1H),8.55(d,J=2.0Hz,1H),8.43 (d,J=2.0Hz,1H),7.98-7.91(m,3H),7.80-7.65(m,5H),2.97(d,J=12.4Hz,6H).

[0177] Example 18 Amino-5-(3-(4-carbamoylphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide (IC-2)

[0178]

[0179] Dissolve 4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid (0.23 g, 0.56 mmol) in tetrahydrofuran (3 mL). Then add DIEA (281 ul, 1.69 mmol) and CDI (0.14 g, 0.84 mmol). The reaction mixture was reacted at room temperature for 2 hours, and then NH3.H2O (0.2 ml) was added and the reaction was continued at room temperature for 2 hours. The reaction solution was quenched with water (5 ml), extracted with ethyl acetate (10 ml*3), and the organic phase was spin-dried and mixed with silica gel. Normal phase purification (dichloromethane / methanol = 10:1) gave the target compound (white solid, 0.20 g, yield 70.2%). LC-MS (ESI) m / z 400.2 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ12.08(s,1H),8.52(d,J=8.0Hz,1H),8.40(d,J=2.4Hz,1H),8.02-7.86(m,6H),7.59(dd,J 1=2.4Hz,J 2=8.4Hz,1H),7.48(d,J=2.0Hz1H),7.29(s,1H),6.93(d,J=8.4Hz,1H)2.99(s,6H).

[0180] Example 19 Synthesis of 2-amino-5-(4-chloro-3-(4-(methylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,n-dimethylbenzamide (IC-3)

[0181]

[0182] Step 1: 4-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid

[0183] 5-Bromo-3-iodo-1H-pyrrolo[2,3-b-and]pyridine (3.00 g, 7.09 mmol) and (4-(methylcarbamoyl)phenyl)boronic acid (1.40 g, 7.82 mmol) were dissolved in 70 mL of 1,4-dioxane solution, and then K2CO3 (2.89 g, 21.30 mmol) in water (14 mL) and Pd(dppf)Cl2 (0.51 g, 0.70 mmol) were added. The reaction solution was evacuated and replaced with argon three times. Heat to 80°C and stir for 2 hours. The reaction solution was quenched with water (20 mL), extracted with ethyl acetate (30 mL*3), washed with brine (30 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1:1) to obtain the target compound (white solid, 0.80 g, yield 26.7%). LC-MS (ESI) m / z 330.0 [M+H] + .

[0184] Step 2: 4-(5-(4-amino-3-(dimethylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid

[0185] Dissolve 4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid (0.55 g, 1.28 mmol) and tert-butyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (0.55 g, 1.41 mmol) in 13 mL of 1,4-dioxane solution, then add Cs2CO3 (1.25 g, 3.84 mmol) water (2.5 mL) solution and Pd(dppf)Cl2 (0.095) g, 0.013 mmol). The reaction solution was evacuated and replaced with argon three times. Heat to 90°C and stir for 2 hours. The reaction solution was quenched with water (10 mL), extracted with ethyl acetate (10 mL*3), washed with brine (10 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by normal phase (dichloromethane / methanol = 40:1) to obtain the target compound (brown solid, 0.60 g, yield 74.8%). LC-MS (ESI, m / z) 414.2 [M+H] + .

[0186] Example 20 4-(5-(4-amino-3-(dimethylcarbamoyl)-5-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid (IC-4)

[0187]

[0188] Dissolve 4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid (0.94 g, 2.17 mmol) and 2-amino-3-fluoro-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.80 g, 2.60 mmol) in 22 mL of 1,4-dioxane solution, then add 4.4 mL of Cs2CO3 (2.10 g, 6.51 mmol) aqueous solution and Pd(dppf)Cl2 (0.11 g, 0.22 mmol). The reaction solution was evacuated and replaced with argon three times. Heat to 90°C and stir for 2 hours. The reaction solution was quenched with water (10 mL), extracted with ethyl acetate (10 mL*3), washed with brine (10 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by normal phase (dichloromethane / methanol = 40:1) to obtain the target compound (light yellow solid, 0.72 g, yield 62.4%). LC-MS (ESI) m / z 419.2 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ12.10(s,1H),8.53(d,J=2.0Hz,1H),8.43(d,J=2.0Hz,2H) ,8.07-7.92(m,5H),7.61(d,J=14.4Hz,2H),7.31(s,1H),5.24(s,2H),2,94(s,6H).

[0189] Example 21 2-amino-5-(3-(4-carbamoylphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-3-fluoro-N,N-dimethylbenzamide (IC-5)

[0190]

[0191] Dissolve 4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)benzamide (0.94 g, 2.17 mmol) and 2-amino-3-fluoro-N, n-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.80 g, 2.60 mmol) in 22 mL of 1,4, dioxane solution, then add 4.4 mL of Cs2CO3 (2.10 g, 6.51 mmol) aqueous solution and Pd(dppf)Cl2 (0.11 g, 0.22 mmol). The reaction solution was evacuated and replaced with argon three times. Heat to 90°C and stir for 2 hours. The reaction solution was quenched with water (10 mL), extracted with ethyl acetate (10 mL*3), washed with brine (10 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by normal phase (dichloromethane / methanol = 40:1) to obtain the target compound (white solid, 0.72 g, yield 62.4%). LC-MS (ESI) m / z 418.3 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ12.06(s,1H),8.52(d,J=2.0Hz,1H),8.41(d,J=2.0Hz,1H),8.02-7.88(m,6H),7.62-7.58(m,1H),7.30(s,1H),2.98(s,6H).

[0192] Example 22 6-amino-3-(3-(4-carbamoylphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-fluoro-N,N-dimethylbenzamide (IC-6)

[0193]

[0194] Dissolve 4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid (0.69 g, 2.17 mmol) and 6-amino-2-fluoro-N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.80 g, 2.60 mmol) in 22 mL of 1,4, dioxane solution, then add 4.4 mL of Cs2CO3 (2.10 g, 6.51 mmol) aqueous solution and Pd(dppf)Cl2 (0.11 g, 0.22 mmol). The reaction solution was evacuated and replaced with argon three times. Heat to 90°C and stir for 2 hours. The reaction solution was quenched with water (10 mL), extracted with ethyl acetate (10 mL*3), washed with brine (10 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by normal phase (dichloromethane / methanol = 40:1) to obtain the target compound (light yellow solid, 0.58 g, yield 64.0%). 1 H-NMR(400MHz,DMSO-d6)δ:12.11(1H,s),8.35(1H,s),8.31(1H,s),8.04(1H,s),7.97-7.99(2H,m),7.83-7.85( 2H,m),7.33-7.35(1H,m),6.64-6.67(1H,m),5.42(2H,s),3.01(3H,s),2.92(3H,s).LC-MS(ESI,m / z)419.1[M+H] + .

[0195] Example 23 Synthesis of 6-amino-3-(3-(4-carbamoylphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-fluoro-N,n-dimethylbenzamide (IC-7)

[0196]

[0197] N, N-diisopropylethylamine (335uL, 2.01mmol) and dicarbonyl imidazole (0.34g, 2.01mmol) were added to a solution of 6-amino-3-(3-(4-carbamoylphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-fluoro-N, N-dimethylbenzamide (0.28g, 0.67mmol) in tetrahydrofuran (7mL), and the reaction solution was stirred at room temperature for 2 hours. Ammonia water (2.5mL) was then added to the above reaction solution, and the reaction solution was stirred at room temperature for 2 hours. The reaction solution was concentrated, mixed with silica gel, and purified by normal phase (dichloromethane / methanol = 10:1) to obtain the target compound (0.21g, yield 75.1%). LC-MS (ESI, m / z) 418.2 [M+H] + .

[0198] Example 24 2-amino-N,N-dimethyl-5-(3-(4-((methylamino)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide (ID-1)

[0199]

[0200] Step 1: 1-(4-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)-N-methylmethanamine

[0201] Under nitrogen protection, 4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N-methylbenzamide (660 mg, 2 mmol) was dissolved in anhydrous tetrahydrofuran, cooled in an ice bath, and 1M lithium aluminum tetrahydride tetrahydrofuran (5 mL, 5 mmol) solution was slowly added dropwise. After addition, the mixture was heated to room temperature and stirred for 3 h. 1 mL of water was added to quench the mixture, and anhydrous magnesium sulfate (2 g) was added and stirred for about 30 min. The mixture was filtered and concentrated to obtain the target compound (570 mg, yield 90%). LC-MS (ESI, m / z) 316.0 [M+H] + Step 2: 2-amino-N,N-dimethyl-5-(3-(4-((methylamino)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide

[0202] Dissolve 1-(4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)-N-methylmethylamine (500 mg, 1.50 mmol) and 2-amino-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinamide (0.80 g, 2.60 mmol) in 22 mL of 1,4, dioxane solution, then add 4.4 mL of Cs2CO3 (2.10 g, 6.51 mmol) aqueous solution and Pd(dppf)Cl2 (0.11 g, 0.22 mmol). The reaction solution was evacuated and replaced with argon three times. Heat to 90°C and stir for 2 hours. The reaction solution was quenched with water (10 mL), extracted with ethyl acetate (10 mL*3), washed with brine (10 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by normal phase (dichloromethane / methanol = 40:1) to obtain the target compound (light yellow solid, 0.43 g, yield 72.0%). LC-MS (ESI) m / z 400.2 [M+H] + .

[0203] Example 25: 2-amino-5-(4-chloro-3-(4-((methylamino)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide (ID-2)

[0204]

[0205] Step 1: 4-(5-Bromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-N-methylbenzamide

[0206] 5-Bromo-4-chloro-3-iodo-1H-pyrrolo[2,3-b-and]pyridine (3.00 g, 7.09 mmol) and (4-(methylcarbamoyl)phenyl)boronic acid (1.40 g, 7.82 mmol) were dissolved in 70 mL of 1,4-dioxane solution, and then K2CO3 (2.89 g, 21.30 mmol) in water (14 mL) and Pd(dppf)Cl2 (0.51 g, 0.70 mmol) were added. The reaction solution was evacuated and replaced with argon three times. Heat to 80°C and stir for 2 hours. The reaction solution was quenched with water (20 mL), extracted with ethyl acetate (30 mL*3), washed with brine (30 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1:1) to obtain the target compound (white solid, 0.80 g, yield 26.7%). LC-MS (ESI) m / z 366.0 [M+H] + .

[0207] Step 2: 1-(4-(5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)-N-methylmethanamine

[0208] Under nitrogen protection, 4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-N-methylbenzamide (660 mg, 2 mmol) was dissolved in anhydrous tetrahydrofuran, cooled in an ice bath, and 1M lithium aluminum tetrahydride tetrahydrofuran (5 mL, 5 mmol) solution was slowly added dropwise. After addition, the mixture was heated to room temperature and stirred for 3 h. 1 mL of water was added to quench the mixture, and anhydrous magnesium sulfate (2 g) was added and stirred for about 30 min. The mixture was filtered and concentrated to obtain the target compound (570 mg, yield 90%). LC-MS (ESI, m / z) 352 [M+H] + .

[0209] Step 3: 2-amino-5-(4-chloro-3-(4-((methylamino)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide

[0210] Dissolve 4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid (0.55 g, 1.28 mmol) and tert-butyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamate (0.55 g, 1.41 mmol) in 13 mL of 1,4-dioxane solution, then add Cs2CO3 (1.25 g, 3.84 mmol) water (2.5 mL) solution and Pd(dppf)Cl2 (0.095) g, 0.013 mmol). The reaction solution was evacuated and replaced with argon three times. Heat to 90°C and stir for 2 hours. The reaction solution was quenched with water (10 mL), extracted with ethyl acetate (10 mL*3), washed with brine (10 mL*3), and dried over anhydrous sodium sulfate. The organic phase was spin-dried and mixed with silica gel, and purified by normal phase (dichloromethane / methanol = 40:1) to obtain the target compound (brown solid, 0.60 g, yield 74.8%). LC-MS (ESI, m / z) 434 [M+H] + .1H NMR (400MHz, DMSO-d6) δ12.28(s,1H),8.18(s,1H),7.65(s,1H),7.56(d,J=7.8Hz,2H),7.45(d,J=7.6Hz,2H),7.20(dd,J =8.4,2.0Hz,1H),7.10(d,J=2.0Hz,1H),6.79(d,J=8.4Hz,1H),5.35(s,2H),4.07(s,2H),2.96(s,6H),2.54-2.53(m,4H).

[0211]

[0212] Example 28 (H8418) Synthesis of (E)-2-amino-5-(3-(3-amino-3-oxoprop-1-en-1-yl)-4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide (IA-9)

[0213]

[0214] Step 1: 2-amino-5-(4-chloro-3-formyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide (IA-9-1)

[0215] 5-Bromo-4-chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxaldehyde (0.91 g, 3.51 mmol) and 2-amino-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (1.22 g, 4.21 mmol) were dissolved in dioxane (15 mL), and then a solution of cesium carbonate (3.20 g, 9.82 mmol) in water (5 mL) was added, and nitrogen was replaced three times. Pd(dppf)Cl2 (0.257 g, 350.69 μmol) was added to the reaction mixture, and nitrogen was replaced three times, and the mixture was heated to 100°C and stirred for 5 hours. The reaction solution was poured into water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain the target compound (0.68 g). LC-MS (ESI, m / z) 343 [M+1] + .

[0216] Step 2: (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)phenyl)-4-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (IA-9-2)

[0217] 2-Amino-5-(4-chloro-3-formyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide (Compound IA-9-1, 0.20 g, 0.583 mmol) and malonic acid (0.607 g, 5.83 mmol) were dissolved in 4 mL of pyridine solution, and then piperidine (0.4 mL) and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.4 mL) were added, and the temperature was raised to 70°C and stirred for 16 hours. The reaction solution was concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain the target compound (136 mg). LC-MS (ESI, m / z) 385 [M+H] + .

[0218] Step 3: (E)-2-amino-5-(3-(3-amino-3-oxoprop-1-en-1-yl)-4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide (IA-9)

[0219] (E)-3-(5-(4-amino-3-(dimethylcarbamoyl)phenyl)-4-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid (Compound IA-9-2, 0.12 g, 0.312 mmol) and N,N'-carbonyldiimidazole (0.061 g, 0.374 mmol) were dissolved in 3.5 mL of tetrahydrofuran solution, and then N,N-diisopropylethylamine (0.081 g, 0.624 mmol) was added and reacted at room temperature for 2 hours. Then 0.3 mL of concentrated aqueous ammonia was slowly added and the reaction was continued at room temperature for another 2 hours. The reaction solution was concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain the target compound (93 mg). LC-MS (ESI, m / z) 384 [M+H] + .

[0220] Examples 25-27 Compounds (Table 1) Reference

[0221]

[0222]

[0223] The intermediates of structures shown in Examples 31 to 37 were synthesized by referring to the method of Example 1

[0224]

[0225]

[0226] Example 38 Synthesis of 2-amino-5-(3-(4-carbamoylphenyl)-4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide (IC-8) (H8445)

[0227]

[0228] Step 1: 4-(5-Bromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)benzamide

[0229] 5-Bromo-4-chloro-3-iodo-1H-pyrrolo[2,3-b-and]pyridine (3.00 g, 8.39 mmol) and (4-(methylcarbamoyl)phenyl)boronic acid (1.38 g, 8.39 mmol) were dissolved in 1,4-dioxane (35 mL), and then potassium carbonate (2.90 g, 20.99 mmol) in water (15 mL) and Pd(dppf)Cl2 (0.614 g, 0.839 mmol) were added. The nitrogen was replaced three times, heated to 80°C, and stirred for 2 hours. The reaction solution was poured into water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1:1) to obtain the target compound (1.48 g). LC-MS (ESI, m / z) 352 [M+H].

[0230] Step 2: 2-amino-5-(3-(4-carbamoylphenyl)-4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide

[0231] 4-(5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)benzamide (0.55 g, 1.57 mmol) and 2-amino-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.46 g, 1.57 mmol) were dissolved in 1,4-dioxane (10 mL), and then cesium carbonate (1.25 g, 3.84 mmol) water (2.5 mL) solution and Pd(dppf)Cl2 (0.095) g, 0.013 mmol) were added. The atmosphere was replaced with nitrogen three times, heated to 90°C, and stirred for 2 hours. The reaction solution was poured into water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol) to obtain the target compound (0.368 g). LC-MS (ESI, m / z) 434 [M+H] + .

[0232]

[0233]

[0234]

[0235]

[0236]

[0237] Example 57 2-amino-5-(4-chloro-3-(4-cyanophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide

[0238]

[0239] Step 1: 4-(5-Bromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)benzonitrile (IE-1-1)

[0240] Dissolve 5-bromo-4-chloro-3-iodo-1H-pyrrolo[2,3-b-and]pyridine (3.00 g, 8.39 mmol) and (4-cyanophenyl)boronic acid (1.23 g, 8.39 mmol) in 1,4-dioxane (35 mL), then add potassium carbonate (2.90 g, 20.99 mmol) in water (15 mL) and Pd(dppf)Cl2 (0.614 g, 0.839 mmol), replace with nitrogen three times, heat to 80 ° C, and stir for 2 hours. Pour the reaction solution into water, extract with ethyl acetate, wash with brine, dry with anhydrous sodium sulfate, filter, concentrate the filtrate, and purify the residue by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain the target compound (1.28 g). LC-MS (ESI) m / z 334 [M+H] + .

[0241] Step 2: 2-amino-5-(4-chloro-3-(4-cyanophenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-N,N-dimethylbenzamide (IE-1)

[0242] 4-(5-bromo-4-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)benzonitrile (0.60 g, 1.80 mmol) and 2-amino-N, N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.523 g, 1.80 mmol) were dissolved in 1,4, dioxane (12 mL), and then cesium carbonate (1.47 g, 4.51 mmol) water (3 mL) solution and Pd(dppf)Cl2 (0.132 g, 0.18 mmol) were added. Nitrogen was replaced three times, heated to 90°C, and stirred for 2 hours. The reaction solution was poured into water, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified with silica gel compound (dichloromethane / methanol) to obtain the target compound (0.60 g). LC-MS (ESI, m / z) 416 [M+H] + ; 1H NMR (400MHz, DMSO-d6): δ12.44(s,1H),8.21(s,1H),7.89-7.79(m,3H),7.72(d,J=8.0Hz,2H),7. 21(dd,J=8.4,2.0Hz,1H),7.12(d,J=2.0Hz,1H),6.80(d,J=8.4Hz,1H),5.36(s,2H),2.96(s,6H).

[0243]

[0244]

[0245]

[0246] Effect Example 1 Biological Assay

[0247] Staurosporine was used as a positive control compound. In this experiment, we used the ADP_GLO method to test the inhibition of some compounds disclosed in this article on the activity of HPK1 kinase (supplier: Invitrogen, batch number: 1993902).

[0248] 1. Experimental operation:

[0249] (1) Prepare 1× buffer.

[0250] (2) Preparation of compound concentration gradient: Compound IC 50 The starting concentration of the assay is 10uM, 3-fold dilution, 10 concentrations, and duplicate well detection. Dilute to 100 times the final concentration of 100% DMSO solution in the 384source plate. Use the dispenser Echo 550 to transfer 50nl of the 100 times final concentration of the compound to the destination plate 384-well plate. Add 50μl DMSO to the positive and negative control wells.

[0251] (3) Use 1× buffer to prepare a kinase solution with a final concentration of 2.

[0252] (4) Add 2.5 μl of kinase solution at twice the final concentration to the compound wells and positive control wells respectively; add 2.5 μl of 1× buffer to the negative control wells.

[0253] (5) Centrifuge at 1000 rpm for 1 min and incubate at room temperature for 15 min.

[0254] (6) Use 1× buffer to prepare a mixed solution of ATP and substrate with a final concentration of 2 times.

[0255] (7) Add 2.5 μl of a mixed solution of ATP and substrate at twice the final concentration and incubate at room temperature for 90 min.

[0256] (8) Add 5 μL of R1 solution (from ADP-Glo) to each well of the reaction plate. TM Kit), centrifuge at 1000 rpm for 1 min, and incubate at room temperature for 60 min.

[0257] (9) Add 10 μL of R2 solution (from ADP-Glo) to each well of the reaction plate. TM Kit), centrifuge at 1000 rpm for 1 min, and incubate at room temperature for 60 min.

[0258] (10) Read using EnVision.

[0259] 2. Data Analysis

[0260] Calculation formula

[0261]

[0262] Fitting dose-effect curve

[0263] The log value of the concentration was used as the X-axis and the percentage inhibition rate was used as the Y-axis. The log (inhibitor) vs. response-Variable slope of the analysis software GraphPad Prism 5 was used to fit the dose-effect curve to obtain the IC value of each compound on the enzyme activity. 50 value.

[0264] 3. Experimental results

[0265] Table 1. Enzyme activity IC of some compounds disclosed in this article 50 (nM)

[0266] Compound No. Enzyme activity Compound No. Enzyme activity IA-1 A IC-1 A IA-2 A IC-2 A IA-3 A IC-3 A IA-4 A IC-4 B

[0267] *A:<100nM,B:100-500nM;C:500nM-1000nM;D:1000-10000nM;E:>10000nM

[0268] Table 2: Enzyme activity IC of some compounds further disclosed herein 50 (nM), specifically

[0269]

[0270]

[0271] / Indicates that no data is available.

[0272] Effect Example 2 Determination of the inhibitory activity of the compounds of the present invention on pSLP76 (S376) cells (HTRF method)

[0273] The Jurkat cell line was used in this study. The cells were maintained in RPMI 1640 supplemented with heat-inactivated 10% fetal bovine serum (Thermo Fisher), 50 units / mL penicillin and streptomycin (Thermo Fisher), and maintained at 37°C in a humidified atmosphere of 5% CO2 in air. Cells were recovered from frozen stocks accumulated (laiddown) from purchased original cells within 30 generations. After starvation of cells for 18 hours in assay buffer (RPMI1640 supplemented with heat-inactivated 0.1% fetal bovine serum), cells were seeded into round-bottom 96-well plates at a density of 150,000 cells per well. Cells were treated with a 9-point dilution series of test compounds. The final compound concentration was 0 to 2 μM. After 2h compound treatment, cells were stimulated for 30 min at 37°C with 0.05 μg / mL anti-human CD3 (OKT3, Bioxcell). The cells were then lysed and the levels of pSLP76 (S376) in the cell lysates were detected by HTRF kit (Cisbio). A total of 16 μL of cell lysates from each well of the 96-well plate were transferred to a 384-well low-volume white assay plate. The lysates from each well were incubated with 2 μL of anti-phospho-SLP76 labeled with Eu3+-cryptate (donor) and 2 μL of anti-phospho-SLP76 antibody labeled with D2 (acceptor) (Cisbio) at room temperature overnight in the dark. The FRET signal (655 nm) was measured using a PHERAstar FSX reader (BMG Labtech). IC was calculated by fitting the curve of percent inhibition versus the logarithm of inhibitor concentration using Dotmatics. 50 Sure.

[0274] Table 3. Inhibition of pSLP76 (S376) activity by compounds of the present invention

[0275]

[0276]

[0277] It will be appreciated that, even if a prior art publication is referred to herein, this reference does not constitute an admission that the publication forms part of the common general knowledge in the art in any country.

[0278] The disclosures of all publications, patents, patent applications, and published patent applications mentioned herein by identifying citations are hereby incorporated by reference in their entirety.

[0279] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A compound of formula I or II, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof: in: R 1 Selected from C 1-6 Alkyl, amino, monosubstituted or disubstituted amine, the monosubstituted amine is selected from methylamine, ethylamine, trifluoroethylamine, isopropylamine, cyclopropylamine, the disubstituted amine is selected from dimethylamine, diethylamine, azetidine, tetrahydropyrrole or substituted tetrahydropyrrole, the substituent of the substituted tetrahydropyrrole is selected from C 1-3 Alkyl, halogen, hydroxyl, alkoxy (preferably the alkoxy is selected from C 1-3 alkoxy), amino, alkylamino (preferably the alkylamino is selected from C 1-3 alkylamino), piperidine or substituted piperidinyl, wherein the substituent of the substituted piperidinyl is selected from C 1-3 Alkyl or halogen, hydroxyl, alkoxy (preferably the alkoxy is selected from C 1-3 alkoxy), amino, alkylamino, morpholine or substituted morpholinyl, wherein the substituent of the substituted morpholinyl is selected from C 1-3 Alkyl or halogen, hydroxyl, alkoxy (preferably the alkoxy is selected from C 1-3 alkoxy), amino, alkylamino (preferably the alkylamino is selected from C 1-3 alkylamino), piperazine, substituted piperazinyl, wherein the substituent of the substituted piperazinyl is selected from C 1-3 Alkyl or halogen, hydroxyl, alkoxy (preferably the alkoxy is selected from C 1-3 alkoxy), amino, alkylamino (preferably the alkylamino is selected from C 1-3 alkylamino groups); R 2 is selected from amino or alkoxyacyl protected amino, wherein the alkoxy is C 1-6 Alkoxyacyl; R 3 is selected from hydrogen, halogen, methyl, trifluoromethyl; R 4 Selected from hydrogen, halogen, C 1-6 alkyl; R 5 is selected from hydrogen, halogen, methyl, trifluoromethyl; R 6 Selected from hydrogen, halogen, C 1-6 Alkoxyacyl; R 7 is selected from hydrogen, methoxymethylene, 2-(trimethylsilyl)ethoxymethylene, 2-tetrahydropyranyl, benzyl, p-methoxybenzyl, tert-butoxyacyl, benzenesulfonyl, toluenesulfonyl; R 8 Selected from hydroxyl, C 1-6 Alkoxy, amine, hydroxylamine, C 1-6 Alkoxyamino, cyano, monosubstituted or disubstituted amine, wherein the monosubstituted amine is selected from methylamino, ethylamino, trifluoroethylamino, isopropylamino, cyclopropylamino, polyhydroxy-substituted C 1-6 Alkyl, the disubstituted amine group is selected from dimethylamino, diethylamino, azetidine, tetrahydropyrrole, piperidine, morpholine, piperazine, NC 1-3 Alkylpiperazine; X is selected from CH, C-halogen or N; L is selected from C 1-3 Alkylene, C 2-3 Alkenylene, C 2-3 Alkyne, optionally substituted aryl, optionally substituted heteroaryl or 3-7 membered heterocyclic group, preferably the substituent of L is selected from halogen, C 1-4 Alkyl, C 1-4 Alkoxy; Y is selected from oxygen, sulfur or NH; Z is selected from nitrogen or -CR 9 ; R 9 is selected from hydrogen and halogen; Preferably, the halogen is selected from fluorine, chlorine, bromine or iodine.

2. A compound of the structure shown in Formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof: in: R 1 Selected from C 1-6 Alkyl, amino, monosubstituted or disubstituted amine, the monosubstituted amine is selected from methyl, ethyl, trifluoroethyl, isopropyl, cyclopropyl, and the disubstituted amine is selected from dimethylamino, diethylamino, azetidine, tetrahydropyrrole, piperidine, and morpholine; R 2 is selected from amino or alkoxyacyl protected amino, wherein the alkoxy is C 1-6 Alkoxyacyl; R 3 is selected from hydrogen, halogen, methyl, trifluoromethyl; R 4 Selected from hydrogen, halogen, C 1-6 alkyl; R 5 is selected from hydrogen, halogen, methyl, trifluoromethyl; R 6 Selected from hydrogen, halogen, C 1-6 Alkoxyacyl; R 7 is selected from hydrogen, methoxymethylene, 2-(trimethylsilyl)ethoxymethylene, 2-tetrahydropyranyl, benzyl, p-methoxybenzyl, tert-butoxyacyl, benzenesulfonyl, toluenesulfonyl; R 8 Selected from hydroxyl, C 1-6 Alkoxy, amine, hydroxylamine, C 1-6 Alkoxyamino, monosubstituted or disubstituted amine, the monosubstituted amine is methylamino, ethylamino, trifluoroethylamino, isopropylamino, cyclopropylamino, and the disubstituted amine is selected from dimethylamino, diethylamino, azetidine, tetrahydropyrrole, piperidine, and morpholine; X is selected from CH, C-halogen or N, wherein the halogen is a fluorine, chlorine, bromine or iodine atom; L is selected from C 1-3 Alkylene, alkenyl, alkynyl, aryl, heteroaryl or 3-7 membered heterocyclic group; Y is selected from oxygen, sulfur or NH; Z is nitrogen or -CR 9 ; R 9 Selected from hydrogen and halogen.

3. The compound of formula I or II according to any one of claims 1 or 2, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that L is selected from C2 alkylene, C2 alkenylene, C2 alkynylene, phenyl, phenyl substituted with halogen atoms, C 1-3 Alkyl-substituted phenyl, pyridyl, halogen-substituted pyridyl, C 1-3 Alkyl-substituted pyridyl, or 3-7 membered heterocyclic group.

4. A compound of formula I or II according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, characterized in that The compound represented by formula I or formula II has the following structure:

5. The compound of formula I according to any one of claims 1 to 4, characterized in that: The linking group L shown in the general formula (I) is an alkenyl group, namely IA, and its synthesis method comprises the following steps: 1) Suzuki coupling of intermediate II and arylboronic acid III to obtain intermediate IV; 2) subjecting the intermediate IV to a Perkin reaction with malonic acid (V) to obtain the intermediate VI; 3) The carboxylic acid of intermediate V is condensed with amine and then deprotected to obtain the target compound IA 6. The compound of formula I according to any one of claims 1 to 4, characterized in that: The connecting group L of the compound represented by general formula (I) is an alkylene group, namely IB, and its synthesis method comprises the following steps: 1) Hydrogenate the double bond of IA to obtain IB.

7. A method for synthesizing a compound represented by the structure of formula I according to any one of claims 1 to 4, characterized in that: When the linking group L of the compound represented by general formula (I) is an aryl group or a heteroaryl group, and Y is oxygen, that is, IC, the synthesis method thereof comprises the following steps: 1) Suzuki reaction of intermediate VII with arylboronic acid VIII to obtain intermediate X 2) Suzuki coupling of intermediate X and arylboronic acid III, followed by deprotection, yields target compound IC 8. A method for synthesizing a compound represented by the structure of formula I according to any one of claims 1 to 4, characterized in that: When the linking group L of the compound represented by general formula (I) is an aryl group or a heteroaryl group, and Y is oxygen, that is, IC, its synthesis method 2 comprises the following steps:

9. A method for synthesizing a compound represented by the structure of formula Ⅱ according to any one of claims 1 to 4, characterized in that: When the compound represented by general formula (II) has a connecting group L of phenyl, Y of hydrogen, and R8 of substituted amino, that is, II-D, Its synthesis method comprises the following steps: 1) Reduce the carbonyl group of intermediate XII with borane or lithium aluminum hydride to obtain intermediate XIV 2) Suzuki coupling of intermediate XIV and arylboronic acid III, followed by deprotection, yields target compound II-D 10. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a compound of the structure shown in Formula I or Formula II as described in any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof and a pharmaceutically acceptable excipient.

11. Use of a compound of formula I or II according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a pharmaceutical composition according to claim 10 in the preparation of a serine / threonine kinase (HPK1) inhibitor.

12. Use of a compound of formula I or II according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a pharmaceutical composition according to claim 10 in the preparation of a drug for treating cancer, autoimmune diseases or inflammatory diseases.

13. The use according to claim 12, characterized in that The cancer is selected from solid tumors or blood cancers.

14. The use according to claim 12, characterized in that The disease is selected from the group consisting of acute myeloid leukemia, liver cancer, gastric cancer, lung cancer, colon cancer, bladder cancer, breast cancer, cervical cancer, pancreatic cancer, melanoma, systemic lupus erythematosus, psoriasis, arthritis, autoimmune diseases or inflammatory reactions.